Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

In August, the U.S. Food and Drug Administration (FDA) stated that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but ...

Biogen Inc. (NASDAQ:BIIB) is the Best Biotech Stock. On April 20, 2026, Reuters reported that Biogen Inc. (NASDAQ:BIIB) had agreed to pay up to $850 million for the exclusive Greater China rights to ...

Looking ahead to 2030, our model projects BIIB could trade at an average price of $355.70, with a potential range between $266.78 and $444.63. This represents a potential 79.7% return from today's ...

Biogen Inc. (NASDAQ:BIIB) delivered stronger-than-expected results for the fourth quarter of 2025 and paired them with a confident profit outlook for 2026, lifting its shares modestly higher following ...

Biogen BIIB reported upbeat earnings for the first quarter on Wednesday. The company posted quarterly earnings of $3.57 per ...

Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was upgraded to Buy from Neutral by UBS, with the firm adjusti ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the June 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...

Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings. The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug ...

Learn more Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set ...